This study will evaluate the occurrences of Diabetes-related Ketoacidosis (DKA) in adult and pediatric individuals living with Type I diabetes while managing diabetes with Abbott's Continuous Monitoring Systems.
Inclusion Criteria:
Exclusion Criteria:
mohamed.nada@abbott.com
This is a multicentre, single arm, prospective, observational clinical study to determine DKA episodes in adult and pediatric people living with type 1 diabetes who will manage their diabetes by use of a Continuous Dual Glucose Ketone (DGK) sensor for 3 months
Rosedale, Auckland 0632, New Zealand
Claudette@optimalclinicaltrials.com+64 9 303 4987
kshemina@optimalclinicaltrials.com+64 9 303 4987
martin.debock@otago.ac.nz+64 (0) 211956579
jo.sanders@nzcr.co.nz+6433729477
ben.wheeler@otago.ac.nz0064223279429
Tina@optimalclinicaltrials.com+64 9 303 4987
Kim.a@optimalclinicaltrials.com+64 9 303 4987
ryan.paul@tewhatuora.govt.nz07 834 0189
helen.snell@midcentraldhb.govt.nz
David.Feng@nzcr.co.nz6421338986
Trish.Smith@nzcr.co.nz+64 4 333 1726
A Multi-Disciplinary Technology-Based Care for Diabetic Ketoacidosis in Patients With Type 1 Diabetes
Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.
Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System
Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM)
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors
Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes
Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis
Validation and Testing of a Novel Continuous Glucose and Continuous Ketone Monitoring Device in Healthy Volunteers